Stockwinners Market Radar for March 01, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:15 EST Cathie Wood's ARK Investment bought 355.8K shares of Cerus today

19:18 EST Elliott says Salesforce's announcements represent 'progress' - Elliott Investment Management released the following statement on behalf of Managing Partner Jesse Cohn and Senior Portfolio Manager Jason Genrich regarding Salesforce: "Elliott has been in close, substantive dialogue with Salesforce leading up to today's earnings statement. Salesforce's set of announcements today represents progress towards regaining investor trust. The acceleration of margin targets, commitment to responsible capital-return priorities, creation of a business transformation committee and disbanding of the M&A committee are necessary steps forward. These steps are consistent with our recommendations, and we believe they will help restore value at Salesforce. The strength of Salesforce's business and its movement in the right direction are key reasons we are among the company's top investors, but much work remains: Salesforce needs a sustainable leadership plan and a board that demonstrates it can provide accountability through proper oversight. To fully earn back the confidence and support of investors, Salesforce leadership must now deliver on its promises. Elliott intends to continue working with Salesforce as we evaluate the level of engagement necessary to achieve the best outcome for the company."

18:31 EST Lottery.com receives staff listing determination from Nasdaq, to request hearing - Lottery.com announced that on February 23, 2023, the company received a determination letter from The Nasdaq Stock Market LLC advising the company that the Staff had determined that the company had not regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the company was not eligible for a second 180 day period as the company has not filed its periodic reports with the Securities and Exchange Commission and Nasdaq, for the quarters ended June 30, 2022 and September 30, 2022, and as such, it no longer complies with Nasdaq's Listing Rules for continued listing. Nasdaq also confirmed to the company in the determination letter that the failure to timely file those periodic reports each serve as separate and an individual basis for delisting. As previously disclosed, on August 24, 2022, the Staff had notified the company that the bid price of its common stock had closed at less than $1 per share over the previous 30 consecutive business days, and, as a result, did not comply with the Rule. In accordance with Listing Rule 5810(c)(3)(A), the company was provided 180 calendar days, or until February 20, 2023, to regain compliance with the Rule, provided that the company was not able to regain compliance within such period. The company intends to appeal Nasdaq's determination to a hearings panel, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The company also intends to request a stay of the trading suspension (which if not granted, will become effective 15 days after the date of the request). Hearings are typically scheduled to occur approximately 30-45 days after the date of the hearing request.

18:06 EST T-Mobile CEO sells $5.75M in common stock - In a regulatory filing, T-Mobile disclosed that its CEO Michael Sievert sold 40K shares of common stock on February 27th in a total transaction size of $5.75M.

17:25 EST Rocket Lab files to delay 10-K release - In a regulatory filing, Rocket Lab stated: "Rocket Lab USA is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 within the prescribed time period for the reasons set forth below. The Company became a large accelerated filer for the first time at the end of the fiscal year ended December 31, 2022, which resulted in a significantly shortened filing deadline to file its 2022 Form 10-K of 60 days compared to 90 days when the Company was a smaller reporting company and emerging growth company at the end of its prior fiscal year. Additionally, commencing with its 2022 Form 10-K, the Company is now for the first time subject to the requirements of Section 404(b)of the Sarbanes-Oxley Act of 2002. For the foregoing reason, the Company requires additional time to complete the procedures relating to its year-end reporting process, including finalizing those disclosures and conclusions required by Section 404(b)of the SOX Act, and procedures and conclusions relating to management's assessment of the effectiveness of internal controls. The Registrant is working diligently to complete the necessary procedures, and expects to file the 2022 Form 10-K within the extension period provided under Rule 12b-25 under the Securities Exchange Act of 1934, as amended."

17:12 EST Silvergate extends decline following NT 10-K filing, down 19% at $10.91

16:51 EST Box falls 10% to $30.10 after Q4 results and guidance

16:48 EST Funko falls 24% to $8.14 after Q4 earnings miss, below-consensus guidance

16:44 EST Avista files PUC request to increase natural gas base rates - Avista files request with the Public Utility Commission of Oregon, or PUC, to increase natural gas base rates. The proposal is designed to increase overall natural gas base revenue by approximately $11M and is based on a proposed rate of return of 7.59% with a common equity ratio of 50% and a 10.25% return on equity.

16:42 EST Salesforce jumps 15% to $192.00 after Q4 earnings beat, above-consensus guidance

16:41 EST Certara CFO Andrew Schemick to transition to new role, John Gallagher to succeed - Certara (CERT) announced that John Gallagher will succeed Andrew Schemick as CFO, effective April 1. Schemick will transition into a newly created position as senior VP, corporate operations and integration, and he will be focused on supporting John's transition, and then building operational excellence as Certara continues to grow. Gallagher brings almost 25 years of experience to Certara, most recently serving as the CFOof Cue Health (HLTH).

16:37 EST Nephros announces new distribution partnership with Donastar Enterprises - Nephros announced a new partnership engaging Donastar Enterprises as the exclusive master distributor for Nephros commercial filters in the food & beverage and hospitality markets. Pursuant to this agreement, Donastar has committed to leveraging Nephros as its principal supplier of commercial water filters.

16:36 EST Organogenesis reports interim analysis of knee osteoarthritis trial - Organogenesis reported the outcome of the interim analysis of its Phase 3 clinical trial for the management of symptoms associated with knee osteoarthritis. The pre-specified interim analysis on 50% of the 474 required patients with moderate to severe knee osteoarthritis focused on the six-month primary endpoint for potential sample size re-estimation. The Independent Data Monitoring Committee, or DMC, for the trial provided directional guidance on the results of the interim analysis, while rigorously maintaining all aspects of study blinding. The DMC recommended that the trial proceed without modification and without increase to sample size. Additionally, the DMC found the safety data to be consistent with the known safety profile for ReNu. The fully enrolled 516 patient Phase 3 trial is a prospective, double-blind, multicenter, placebo-controlled, parallel group, randomized control trial, or RCT, of ReNu, a cryopreserved amniotic suspension allograft, or ASA, for the treatment of subjects with moderate to severe symptomatic knee osteoarthritis, or OA. Patients were randomized to receive a single intra-articular, or IA, injection of either saline control or ReNu. The primary endpoint is the reduction in knee pain assessed by the Western Ontario and McMaster Universities Arthritis Index, or WOMAC, pain scale performed on subjects treated with ReNu or saline. The number of knee replacement surgeries is growing every year and expected to rise from approximately 680,000 Americans in 2014 to 1.28M Americans in 2030.

16:35 EST Aprea Therapeutics regains compliance with Nasdaq minimum bid rule - Aprea Therapeutics announced that it received formal notice from The Nasdaq Stock Market stating that the Company has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Global Select Market as set forth in Nasdaq Listing Rule 5450(a)(1) ."We are excited about regaining compliance and we believe our recent financing, which was supported by quality institutions, has strengthened our balance sheet and enabled the Company to continue developing its clinical asset, ATRN-119, and its pre-clinical asset ATRN-W1051" said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics.

16:33 EST Genworth's backed senior unsecured debt rating upgraded to Ba1 at Moody's - Genworth Financial announced the second ratings upgrade since its fourth quarter earnings results as Moody's Investors Service upgraded the Genworth Holdings, Inc. backed senior unsecured debt rating to Ba1 from Ba2, signifying a one-notch upgrade. The outlook for the rating remains stable. "We are pleased with this upgrade from Moody's, as it further underscores our progress in improving Genworth's financial position," said Tom McInerney, Genworth President and CEO. "We remain committed to investing in our growth initiatives and returning capital to our shareholders."

16:32 EST Invitation Homes names Charles Young president, COO - Invitation Homes announced the promotion of Charles Young to President and Chief Operating Officer. Dallas Tanner will continue in the role of Chief Executive Officer. "We are extremely pleased to expand the role Charles plays in the organization. Over the last decade, he has been an integral leader in helping Invitation Homes and a predecessor company build a robust business and a strong team," said Tanner. "Charles has a deep understanding of the business and strategy and a thoughtful and caring approach to our resident experience, and he is an exceptional leader in the way that he builds relationships and teams."

16:31 EST Choice Hotels raises quarterly dividend 21% to 28.75c from 23.75c per share - Effective with the dividend payable on April 18 to shareholders of record on April 3.

16:30 EST Snowflake, AWS announce multi-year expansion of partnership - Snowflake (SNOW) and Amazon Web Services (AMZN) announced a multi-year expansion of their partnership, with Snowflake growing its AWS spend and both companies jointly contributing millions of dollars to support go-to-market efforts. The expansion of the collaboration will take a deep, multi-faceted approach to fuel growth and drive customer-focused innovation across sales and marketing, industry solutions, product integrations, and more. "Over the past three years, Snowflake and AWS have quickly created what we believe may be one of the most successful technology co-sell partnerships in cloud computing," Snowflake Chairman and CEO, Frank Slootman said. "We are continuing to strengthen our partnership with deep collaborations in industry vertical solutions and product integrations in machine learning capabilities, with a single-minded focus on what's best for our customers."

16:29 EST Radius Global targets deployment of at least $400M of acquisition capex in 2023 - Based on the current pipeline of investment opportunities, management is targeting the deployment of at least $400 million of Acquisition Capex in 2023. As the Company has previously noted, there may be quarterly variability in the amount of capital deployed.

16:13 EST Snowflake authorizes $2B stock repurchase program - Board of Directors has "authorized a stock repurchase program of up to $2.0B of outstanding Class A common stock. Repurchases may be effected, from time to time, either on the open market, in privately negotiated transactions, or through other transactions in accordance with applicable securities laws. The program will be funded using Snowflake's working capital and will expire in March 2025."

16:02 EST Semler Scientific: Published study supports use of QuantaFlo - Semler Scientific announced the publication of a study in the peer-reviewed Journal of Preventive Medicine with data supporting the use of QuantaFlo as an aid to measure hemodynamics related to heart dysfunction. Notably, the study showed a statistically significant correlation between QuantaFlo HD and cardiac echocardiography, which was used as the gold standard for diagnosing heart failure.

15:52 EST GSK says FDA Advisory Committee supports effectiveness and safety of RSV vaccine - GSK plc announced that the U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, or VRBPAC, voted that the available data support the safety and effectiveness of GSK's respiratory syncytial virus, or RSV, older adult vaccine candidate for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 years and older. The Committee voted unanimously 12-0 on effectiveness and 10-2 on safety. Phil Dormitzer, Global Head of Vaccines R&D, GSK said: "Today's vote brings us an important step closer to delivering one of the world's first vaccines for RSV, a respiratory virus that causes potentially debilitating disease and imposes a major burden on healthcare systems. Thousands of older adults in the US are impacted by RSV and those with underlying health conditions, like respiratory and heart diseases and diabetes, are at increased risk of severe complications. We're delighted that the Advisory Committee recognized the strength of our vaccine's data and its potential to make a positive public health impact with a unanimous vote on the effectiveness of the vaccine."

15:31 EST User reports indicate problems at Paramount+, Downdetector says - Reference Link

14:50 EST FBI reports 2.57M NICS firearm background checks in February - The FBI reported that there were 2,565,607 firearm background checks initiated through the NICS system in February 2023. This compares to 2,554,912 checks in February of 2022 and 2,673,921 in January 2023. Companies in the gun space include Sturm, Ruger (RGR), Smith & Wesson Brands (SWBI), and Vista Outdoor (VSTO). Reference Link

14:17 EST North American rail traffic down 3.4% for the week ending February 25 - The Association of American Railroads, AAR reported U.S. rail traffic for the week ending February 25, as well as volumes for February 2023. U.S. railroads originated 905,744 carloads in February 2023, down 1.6% or 15,101 carloads, from February 2022. U.S. railroads also originated 943,979 containers and trailers in February 2023, down 8.4%, or 86,351 units, from the same month last year. Combined U.S. carload and intermodal originations in February 2023 were 1,849,723, down 5.2%, or 101,452 carloads and intermodal units from February 2022. "Coal, chemicals, and grain together account for more than half of all non-intermodal U.S. rail volume. When all three are down, like they were in February, it's very hard for total carloads not to be down too," said AAR Senior Vice President John T. Gray. "On the positive side, several commodities including crushed stone and sand, petroleum products, steel products, grain mill and food products showed very strong performances." Total U.S. weekly rail traffic was 459,233 carloads and intermodal units, down 5.9% compared with the same week last year. Total carloads for the week ending February 25 were 226,435 carloads, up 0.1% compared with the same week in 2022, while U.S. weekly intermodal volume was 232,798 containers and trailers, down 11.1% compared to 2022. North American rail volume for the week ending February 25 on 12 reporting U.S., Canadian and Mexican railroads totaled 327,221 carloads, up 2.9% compared with the same week last year, and 308,029 intermodal units, down 9.3% compared with last year. Total combined weekly rail traffic in North America was 635,250 carloads and intermodal units, down 3.4%. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Greenbrier (GBX), Trinity Industries (TRN), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

14:04 EST Honda reports February U.S. sales down 1.4% to 83,247 units - American Honda reports February sales of 83,247 units units, pointing to a "strong start for Acura brand in 2023" and sales of all-new volume Honda models - CR-V, Accord and Pilot - being temporarily constrained by supply and logistics issues. Honda said those models are "now heading to market with an anticipated boost to sales in March." Reference Link

13:33 EST Volkswagen to combine Volkswagen Financial Services, Volkswagen Bank - Volkswagen announced that the management board of Volkswagen Financial Services Aktiengesellschaft and the board of managing directors of Volkswagen Bank GmbH resolved to initiate a reorganization of the subgroups of Volkswagen Financial Services Aktiengesellschaft and Volkswagen Bank GmbH. "To implement the planned reorganization, the majority of the German and European companies, including the respective subsidiaries and participations, as well as other assets, liabilities and further legal relationships of Volkswagen Financial Services Aktiengesellschaft and Volkswagen Bank GmbH, including its participations, shall be combined and consolidated under a new financial holding company supervised by the ECB. The shares in Volkswagen Leasing GmbH shall be completely transferred to Volkswagen Bank GmbH. The current Volkswagen Financial Services Aktiengesellschaft shall act as a holding company for non-European companies. In the context of the planned measures, existing control and profit and loss transfer agreements shall also be adjusted and extended to the new financial holding company. Both the new financial holding company and the holding company for non-European companies will continue to be an integral part of the Volkswagen Group, but with different geographic business focus. By bundling its activities in a European financial services provider, the refinancing strength of Volkswagen Bank GmbH can best be used for the growth of the leasing business in Germany and Europe. The Volkswagen Group is thus laying the foundation for the successful implementation of the Group's strategy in the mobility sector, taking into account the regulatory framework. It is intended to complete the main steps of the reorganization mid-2024. The implementation of the reorganization is subject to the approval of the supervisory board," the company noted.

13:03 EST Peloton appoints Dalana Brand as CPO - Peloton (PTON) announced the appointment of Dalana Brand as Peloton's Chief People Officer, effective March 13, 2023. She will report to CEO Barry McCarthy and serve as a member of the leadership team, leading the company's Global People Team. Brand previously served as Chief People and Diversity Officer at Twitter (TWTR). Brand is relocating from California and will be based in New York City.

12:40 EST Puyi Inc (ADR) trading halted, volatility trading pause

12:34 EST CEO of Amazon's Ring Jamie Siminoff stepping down - The CEO and founder of Amazon.com's Ring, Jamie Siminoff, announced today that he is stepping down as CEO. He said in a blog post, "Invention is my true passion. I am constantly looking at how we can adapt to deliver for our neighbors, which is what we've always called our customers. This is why I decided to shift my role to Chief Inventor and bring on a new CEO...Today, I'm excited to introduce our new CEO, Elizabeth (Liz) Hamren, who is joining us most recently from Discord where she is COO. Liz has a long history in consumer devices and subscription services, building and launching some of the most innovative and beloved consumer products from Oculus to Xbox and more...Liz will lead Ring, Blink, Amazon Key, and Amazon Sidewalk, starting on March 22. I will focus on inventing even more great products with Liz - and maybe have a little more free time too."

12:25 EST Einhorn discusses Tenet, Consol, Teck Resources longs on CNBC - Greenlight Capital's David Einhorn is speaking on CNBC.

12:14 EST Einhorn says investors should be 'bearish on stocks and bullish on inflation' - Greenlight Capital's David Einhorn is speaking on CNBC.

12:09 EST Boeing chief engineer Greg Hyslop to retire, Howard McKenzie to succeed - Boeing announced that Greg Hyslop, the company's chief engineer and executive vice president of Engineering, Test & Technology, will retire this June after a 41-year career that spanned Boeing's aerospace and defense portfolio. Howard McKenzie, the top engineer at Boeing's commercial airplanes unit, succeeds Hyslop as chief engineer and executive vice president, Engineering, Test & Technology. Effective today, McKenzie takes over leadership of the company's 57,000 engineers worldwide, overseeing all aspects of safety and technical integrity of Boeing products and services. McKenzie also assumes oversight of Boeing's technology vision, strategy and investment, while reporting to Calhoun and joining the company's executive council. David Loffing, chief program engineer of Boeing's new 777X airplane, takes over as vice president and chief engineer of BCA. Hyslop will support the leadership transition through June as he assumes the role of chief engineer emeritus, reporting to Calhoun. He will assist with program management, leadership development and university relations efforts.

12:06 EST Square provides policy and pricing updates - In a blog post, Square said: "Occasionally, Square needs to update policies and pricing for our products to better align to evolving costs from our network and payments partners. In these scenarios, we make pricing changes so that we can invest in our platform, create new features, and continue expanding the value Square provides its sellers. Because we have a growing, multifaceted ecosystem of integrated business and commerce tools, we work carefully across product lines to minimize disruptions and changes. Beginning next month, three new pricing changes are going into effect for Square sellers: updates to our refund policy, changes to paid transfers pricing, and new pricing for our revamped Square Online paid plans. We are updating Square's refund policy so that processing fees will no longer be returned when sellers issue a full or partial refund to their buyers. The fee for instant and same-day transfers is changing from 1.5% to 1.75% per transfer. For ecommerce and omnichannel sellers, we are consolidating the plans we offer for Square Online to 3 distinct tiers - Free, Plus, and Premium - and recalibrating prices across paid plans. For existing sellers in the U.S., the new refund policy and paid transfers pricing will go into effect on April 11, 2023." Reference Link

12:02 EST Lazard acquires Truvvo Partners, terms not disclosed - Lazard Asset Management announced that it has acquired Truvvo Partners, a U.S.-based firm with $3.8B of Assets Under Management, dedicated to providing strategic advice, wealth planning, and investment management to families. Truvvo and LAM have formed Lazard Family Office Partners, which combined will manage approximately $8B in assets, including LAM's existing U.S. private client business, and provide advice and investment solutions across public and private markets. Lazard Family Office Partners will integrate investment management, risk management, and family office services into one offering to help meet the evolving needs of our clients. As a result of Truvvo joining LAM, the firm's global wealth management AUM, including assets managed across the firm's European wealth management business, will total approximately $22B.

12:00 EST Figs falls -25.2% - Figs is down -25.2%, or -$2.32 to $6.89.

12:00 EST Dycom rises 20.1% - Dycom is up 20.1%, or $16.96 to $101.17.

12:00 EST Nerdy rises 29.9% - Nerdy is up 29.9%, or 75c to $3.26.

11:39 EST Alvarium Tiedemann Holdings Inc trading resumes

11:34 EST Alvarium Tiedemann Holdings Inc trading halted, volatility trading pause

11:05 EST Con Edison finalizaes sale of Clean Energy Businesses to RWE Renewables - Consolidated Edison completed the sale of its wholly-owned subsidiary, Con Edison Clean Energy Businesses, including the transfer of substantially all of its assets, to RWE Renewables Americas, LLC. The transaction is valued at $6.8B.

10:50 EST European Biotech Acquisition Corp trading resumes

10:41 EST Windtree Therapeutics Inc trading halted, volatility trading pause

10:09 EST First Horizon, TD extend outside date for pending merger - In a regulatory filing earlier, First Horizon (FHN) stated: "In 2022 we agreed to be acquired by TD for a cash price per FHN common share that, at the close of business on February 20, 2023, was $25.1531488 per share and rising very slightly each day thereafter. The market price of our common stock was and continues to be substantially impacted by the Pending TD Merger. Completion of the Pending TD Merger is subject to customary closing conditions, including approvals from U.S. and Canadian regulatory authorities. On February 9, 2023, FHN and TD agreed to extend the outside date to May 27, 2023. Subsequent to the extension, TD recently informed FHN that TD does not expect that the necessary regulatory approvals will be received in time to complete the Pending TD Merger by May 27, 2023, and that TD cannot provide a new projected closing date at this time. TD has initiated discussions with FHN regarding a potential further extension of the outside date. There can be no assurance that an extension will ultimately be agreed or that TD will satisfy all regulatory requirements so that the regulatory approvals required to complete the Pending TD Merger will be received."

10:00 EST China Jo-Jo Drugstore trading resumes

10:00 EST Tupperware Brands falls -22.1% - Tupperware Brands is down -22.1%, or -91c to $3.19.

10:00 EST Dycom rises 23.9% - Dycom is up 23.9%, or $20.09 to $104.30.

10:00 EST B&G Foods rises 27.6% - B&G Foods is up 27.6%, or $3.50 to $16.17.

09:47 EST Tupperware Brands falls -24.9% - Tupperware Brands is down -24.9%, or -$1.02 to $3.08.

09:47 EST Dycom rises 15.8% - Dycom is up 15.8%, or $13.30 to $97.51.

09:47 EST Nerdy rises 21.9% - Nerdy is up 21.9%, or 55c to $3.06.

09:46 EST China Jo-Jo Drugstore trading halted, volatility trading pause

09:40 EST Knightscope enters contract with Overton Brooks for 10 K1 Blue Light Towers - Knightscope announced that Overton Brooks Veterans Administration Medical Center in Shreveport, Louisiana, executed a contract for 10 new K1 Blue Light Towers.

09:38 EST Linde completes delisting from Frankfurt Stock Exchange - Linde announced that it has completed its intercompany reorganization resulting in the delisting of its shares from the Frankfurt Stock Exchange. As of March 2, 2023, the new holding company, "Linde plc", will be listed solely on the New York Stock Exchange and trade under the existing ticker "LIN". Per the announcement of February 23, 2023, Linde will now apply to the Irish High Court for a capital reduction for the purposes of creating distributable reserves under Irish law. The date of that court hearing shall be published on Linde's website.

09:37 EST Cuentas signs supply agreement with Renco USA for affordable housing projects - Cuentas has signed a 10 year supply agreement with Renco USA to provide its patented building materials for new, sustainable rental housing projects. Renco is an innovative green construction technology company that has a patented MCFR Construction System which provides cost efficiency, reduced build time, and sustainable benefits.

09:36 EST Perrigo announces FDA approval of store brand OTC equivalent of Advil tablets - Perrigo Company received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, the store brand over-the-counter equivalent of Advil Dual Action Tablets 250 mg/125 mg. The Company anticipates launching the product by Spring 2023.

09:34 EST Pop Culture Group applies AIGC to business system - Pop Culture Group has achieved milestones in the field of artificial intelligence such as AIGCand ChatGPT. The application of ChatGPT is under continuous development in the Company's Shenzhen Technology Center while AIGC has been integrated into some of its business segments. Pop Culture has made full use of AIGC in its product design. Focusing on street dance and with IP content as the core, Pop Culture has designed concept drawings of a great many street dance-related products and derivatives through AIGC, such as footwear, apparel, accessories, and garage kits, etc. The Company has also reached manufacturers to successfully unveil these products and sell them online.

09:33 EST Cinedigm approves repurchase program for up to 10M shares - Cinedigm announced that the company's board of directors has approved a stock repurchase program to purchase up to an aggregate of 10M shares of its outstanding Class A common stock. The stock repurchase program will expire on March 1, 2024, unless otherwise modified by the board. "This stock repurchase program, which is effective immediately, is a testimonial to the unwavering confidence the board and management of Cinedigm has in the future of the company and the considerably undervalued price of our common stock. We are on a strategic path that will differentiate us from all others in our industry and produce sustained profitability and growth. We see this stock repurchase program as an exceptional investment opportunity that will further enhance the value of our company in the years ahead," said Chris McGurk, Chairman and CEO of Cinedigm.

09:32 EST IMAC Holdings COO Ben Lerner resigns - In addition to the sale of The BackSpace, the Company's COO Ben Lerner, announced his resignation to pursue other interests. The Company will not replace the COO position and Dr. Matt Wallis, President of IMAC, will continue to manage operating responsibilities for the Company's medical clinic division.

09:31 EST IMAC sells The Backspace to Curis Functional Health, terms not disclosed - IMAC Holdings has completed the sale of The BackSpace for an undisclosed price to Curis Functional Health. The BackSpace offers convenient and affordable spinal health and wellness services in select Walmart locations.

09:30 EST Lionheart III Corp trading halted, volatility trading pause

09:20 EST Tyler Technologies acquires Safeground Analytics, terms undisclosed - Tyler Technologies announced it has acquired Safeground Analytics, a company providing exemplary real estate appraisals and assessments for states, counties, and municipalities. Safeground brings an experienced team of appraisers, analysts, statisticians, economists, computer scientists, and assessors to provide residential and commercial reassessments, bolstering Tyler's existing appraisal services business. Founded by John Valente, Safeground is currently based in Northampton, Massachusetts. The Safeground team will join Tyler's Property & Recording Division but will remain in New England as remote employees. John will serve as Northeast Regional Appraisal Manager.

09:18 EST Xtant acquires Coflex product line from Surgalign for $17M - Xtant Medical Holdings (XTNT) and Surgalign Holdings (SRGA) announced the completion of a transaction between the companies. On February 28, 2023, Xtant Medical and Surgalign entered into a Definitive Agreement and subsequently closed on the transaction whereby Xtant acquired the Coflex and Cofix product lines from Surgalign for a total consideration of $17M. Coflex is an interlaminar stabilization device used after an open decompression that can be performed in various settings, offering a non-fusion treatment option for lumbar spinal stenosis patients. The number of patients diagnosed globally with LSS is approximately 2.4 million representing the largest single-growing patient demographic in spine. The Coflex device is the only FDA PMA-approved implant for the treatment of LSS, has been implanted in more than 200,000 patients in over 60 countries, is clinically validated with more than 90 peer reviewed publications and has established Ambulatory Surgery Center reimbursement. Cofix is a supplemental fixation device, which is a minimally invasive system intended for use on all levels of the lumbar spine.

09:16 EST SuperCom launches $3.6M project for the government of Finland - SuperCom announced it has launched a $3.6M project with the national government of Finland to deploy its PureSecurity Electronic Monitoring, or EM, Suite. This launch follows the progression of the competitive tender win in Finland previously announced, the successful completion of an appeal process, contract negotiations, and contract execution. The goal of this project is to help Finland improve its public safety while reducing prison overcrowding and lowering recidivism using SuperCom's innovative and proven technology and services. The nationwide project is planned to cover all EM offender programs in Finland for four years and include at least 1,000 enrollees simultaneously, with the potential for expansions.

09:12 EST Focus Universal lowers ATM financing agreement amount - Focus Universal has reduced its previously announced at-the-market offering from $25 million to $1 million. Under the agreement, the company has not sold any shares.

09:10 EST Lowe's CEO Ellison: Consumers enjoying 'record levels of equity' in homes

09:08 EST Future FinTech signs acquisition agreement with Alpha Financial - Future FinTech Group announced that on February 27 Future FinTech, a wholly owned subsidiary of the Company, signed a Share Transfer Agreement with Alpha Financial, a firm based in Hong Kong, to acquire its wholly owned subsidiaries Alpha International Securities, a company incorporated in Hong Kong and Alpha Information Service Shenzhen, a company incorporated in China. On September 8, 2022, the Company announced that FTFT HK signed a Memorandum of Understanding with Alpha Financial to acquire Alpha HK. Pursuant to the Agreement, FTFT HK agreed to acquire all of the issued and outstanding shares of Alpha HK and Alpha SZ from Alpha Financial in cash for a price of HK$15,659,949, or approximately $2.007M; 50% of the Total Purchase Price is to be paid to Alpha Financial within 5 working days after the signing of the Agreement with the remaining 50% to be paid within 5 working days after FTFT HK receives approval from the Hong Kong Securities and Futures Commission for the transfer of Alpha HK to FTFT HK prior to December 31. If the HKSFC fails to give such approval within 365 days of the Agreement, Alpha Financial will refund the amount paid by FTFT HK under the terms of the Agreement within 3 working days after the earlier of receiving the notice of failure or the expiration of 365 days unless FTFT HK and Alpha Financial mutually agree to extend such deadline.

09:06 EST Progyny announces partnership with NBA's Detroit Pistons - Progyny announced a partnership with the National Basketball Association's, NBA, Detroit Pistons. Through this partnership, the Detroit Pistons will have access to equitable and comprehensive family building care that its diverse workforce requires. With Progyny, Detroit Pistons employees and their spouses now have access to a family building benefit that delivers an exceptional patient experience and superior clinical outcomes, which means those who seek medical treatment for their infertility are able to get pregnant faster, have healthier pregnancies, and deliver healthier babies. "The Detroit Pistons are leading the charge by being the first NBA team to recognize the importance of providing comprehensive, value-based care for infertility and family building, an essential area of healthcare that is often overlooked," said Pete Anevski, Progyny's CEO. "Family building benefits are a critical healthcare need for employees and their families, and we applaud them for doing what's right for their team."

09:06 EST Lake City Bank receives CFE Fund certifications - Lake City Bank's Essential Checking and Getting Ahead Checking accounts were recently certified by the national Cities for Financial Empowerment Fund as meeting the 2023-24 Bank On National Account Standards. The account standards designate features that ensure low cost accounts with high functionality and consumer safety.

09:06 EST Lowe's saw DIY pullback in holiday spending, says CEO - CEO Marvin Ellison is speaking on the company's Q4 earnings conference call.

09:05 EST PodcastOne renews shows with over 1B downloads - PodcastOne secured renewals for several tentpole programs that keep top performing and fan favorite podcasts with the network for the foreseeable future. The podcasts include: The Adam Carolla Podcast, The Jordan Harbinger Show, LADYGANG, Off The Vine with Kaitlyn Bristowe, and Court Junkies.

09:04 EST Hyundai Motor America reports Feb retail sales of 57,044 units, up 9% y/y - Hyundai Motor America reported total February sales of 57,044 units, a 9% increase compared with February 2022 and the best February in Hyundai history. This was the fourth consecutive month with a total monthly sales record, led by Elantra (+53%), Kona EV (+753%), Kona N (+42%), Santa Cruz (+9%), Tucson (+13%), and Venue (+17%). February was an all-time best-ever retail and total sales month for the Elantra N (+72%) and Santa Fe HEV (+121%). Hyundai fleet sales were 7% of total volume for the month.

09:03 EST Fortinet introduces new cybersecurity products, professional services - Fortinet announced new and enhanced products and services for operational technology environments as an expansion of the Fortinet Security Fabric for OT. Fortinet enables organizations to build a platform of integrated solutions to effectively mitigate cyber risk across OT and IT environments.

09:03 EST Amgen to present new Repatha combined data from Phase 3 FOURIER trials - Amgen announced new Repatha combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, an siRNA that reduces lipoprotein by more than 90%. Additional data from Amgen's Center for Observational Research and Amgen funded investigator studies, including YELLOW-III from Mount Sinai will be presented at the American College of Cardiology's 72nd Annual Scientific Session together with World Heart Federation's World Congress of Cardiology in New Orleans, LA, March 4-6, 2023.

08:57 EST Verses closes $5M tranche, announces upsize of convertible debenture financing - VERSES Technologies has raised gross proceeds of C$5,001,409 under the first tranche of its on-brokered private placement of unsecured convertible debentures units of the Company comprised of Convertible Debentures and Warrants through the sale of unsecured convertible debentures of the Company in the principal amount of C$5,001,409 and 1,742,979 detachable warrants to purchase Class A Subordinate Voting shares of the Company. The Company is also pleased to announce that it has increased the size of the Private Placement for aggregate proceeds of up to C$7,500,000. Closing of additional tranches of the Private Placement remain subject to acceptance by the Neo Exchange. The proceeds from the Private Placement are intended to be used for general working capital purposes. All securities issued pursuant to the Private Placement are and will be subject to a four month hold period from the date of issue. Under the first tranche of the Private Placement, VERSES paid fees to eligible finders consisting of: C$261,360; and 303,907 broker warrants. Each Broker Warrant will entitle the holder thereof to acquire one Share at an exercise price of C$1.00 until August 15, 2025 or on such other terms as required by the NEO. The Units were offered to investors as both Canadian dollar denominated units and United States dollar denominated units and as such, the aggregate proceeds from the initial tranche of the Private Placement were determined in part by reference to the daily average exchange rate of USD$1.00:C$1.3573 on February 27, 2023 as reported by the Bank of Canada.

08:51 EST Imunon sees sufficient capital resources to fund operations into 2025 - IMUNON announced that Dr. Corinne Le Goff, CEO, has issued a letter to shareholders, which read in part, " Several transformative events during 2022 laid the foundation for establishing IMUNON as a platform company with a focus on key disease areas. I was delighted to be named President and Chief Executive Officer in July with the mandate to lead IMUNON through its next stage of growth, drawing upon my experiences at Moderna, Amgen and Roche in infectious diseases, immunology and oncology. I recognized the potential of DNA-based technology to address substantial unmet medical needs and market opportunities in immuno-oncology and infectious diseases...IMUNON is implementing a thoughtful four-pronged business strategy. 1- Focus on immuno-oncology as an asset development opportunity for IMUNON...2- Focus on developing our DNA-based prophylactic vaccine platform as an out-licensing and partnership opportunity...3- Vertical integration of the core elements of our business...4- Strategic collaborations: the bedrock of our business model...We are also actively scouting for new technologies or new assets in areas adjacent to our domain of expertise in immuno-oncology, gene therapy, oligonucleotides and nucleic acids. Our objective is to balance the risk profile of our pipeline by acquiring a third leg to our portfolio of technologies...We have a history of careful cash stewardship along with opportunistic fundraising to advance our vision. In January 2023 we received approximately $1.6 million from the sale of New Jersey net operating losses. Along with $1.8 million in future planned sales of New Jersey NOLs and a thoughtful budget, we believe we have sufficient capital resources to fund our operations into 2025...We expect 2023 will be an active and productive year for IMUNON with the achievement of multiple important milestones. We anticipate filing an Investigational New Drug application with the U.S. Food and Drug Administration for our seasonal COVID-19 booster vaccine. Our objective, as mentioned above, is to confirm in a Phase 1 clinical study the safety of our PLACCINE modality. In the coming months we will apply for a pre-IND consultation with the FDA to receive guidance on our proposed program prior to submitting the IND.We will also announce our next pathogen target for our PLACCINE modality. It is likely that we will choose a pathogen among the list of priority pathogens established by CEPI. We will continue to follow patients enrolled in our OVATION 2 Study and expect to report an additional set of interim, more mature data in the second half of 2023. We recently announced a collaboration with the Break Through Cancer Foundation to evaluate in a Phase 1/2 clinical trial the benefits of IMNN-001 in combination with bevacizumab in ovarian cancer in the frontline, neoadjuvant setting. Working with four of the foremost comprehensive cancer centers in the world, the goal of this project is to transform the care of women with ovarian cancer by developing unprecedented capabilities for understanding and targeting persistent minimal residual disease, as explained here. We look forward to enrolling the first patient in the coming weeks at the University of Texas MD Anderson Cancer Center, with expected additional participation at Dana-Farber Cancer Institute, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Memorial Sloan Kettering Cancer Center. The Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology will provide artificial intelligence services throughout the trial, including biomarker and genomic analyses. This will expand our knowledge of the treatment paradigm. In summary, our technologies hold great promise for patients and their caregivers, and we are extremely excited about the prospects for IMUNON. "

08:49 EST Xtant trading halted, news pending

08:46 EST PSEG files $2.54B extension of its Gas System Modernization Program - PSE&G filed for a three-year, $2.54B extension of its Gas System Modernization Program, or GSMP, with the New Jersey Board of Public Utilities. The proposal would continue the utility's work to update its existing infrastructure to improve reliability and reduce greenhouse gas emissions, or GHG, by replacing aged pipes with modern ones, and sustaining the thousands of jobs and skilled workforce created under GSMP II with the prospect of creating more jobs. In keeping with its continued efforts to improve reliability and reduce methane emissions, the program's replacement of old gas mains is estimated to reduce CO2e emissions by more than 145,000 metric tons. GSMP III Highlights include: exclusively focusing on modernizing existing infrastructure, using advanced management and construction processes to replace old, leaky cast iron pipes and unprotected steel mains with upgraded materials; maintaining the infrastructure and system through better gas flow control and through upgraded equipment, with the aim of enhancing safety; immediate reduction of leaks by installation of new pipes that can also deliver emerging lower-carbon alternatives, including RNG and hydrogen; an estimated 310 miles, or 38%, of the low-pressure cast iron upgrades would be in municipalities that have a significant number of overburdened communities; enabling higher efficiency appliances; and ensuring our customers' power sources remain affordable and diversified.

08:44 EST Jack in the Box signs 14 new restaurant commitments - Jack in the Box announced that it signed 14 new restaurant commitments that will bring Jack in the Box to two new states, Florida and Arkansas. This is the first time the brand has entered the Arkansas market, and over 30 years since it was last in Florida.

08:41 EST SOBR Safe signs SaaS agreement with Native American tribe - SOBR Safe announced that it has signed a software as a service agreement with a prominent Native American tribe, a Self-Governing Nation within the United States that serves thousands of members. The tribe is initially implementing the SOBRcheck technology to ensure that its transit fleet is 100% alcohol-free. Implementation across other critical, safety-sensitive functions is under consideration.

08:40 EST Muscle Maker shareholders approve agreement between Sadot, AGGIA - Muscle Maker announced that its shareholders have voted to approve the terms of the Services Agreement between its wholly owned subsidiary, and AGGIA, pursuant to which Sadot retained AGGIA to perform the day-to-day operations of Sadot. The Agreement provides for issuance of stock to AGGIA upon achieving certain net income along with other consideration. As per the approved terms, AGGIA only earns shares of the Company's common stock if net income is generated by Sadot. The shares of common stock are calculated by dividing the net income generated for an applicable quarter by a premium share price of $1.5625 per share. AGGIA may earn up to 14,424,275 shares of common stock, which would require Sadot generating $22,537,929 in net income. Upon AGGIA earning the maximum amount of shares of common stock, if net income is generated, it shall be accrued as debt.

08:39 EST UWM Holdings anticipates Q1 production $16B-$23B - Mat Ishbia, Chairman and CEO of UWMC, also said, "I want to give a huge thank you to everyone at UWM. It is because of the dedication of our team members and the broker community that 2022 was a historic year. Rest assured, we will not relax in 2023 as there is still much work to be done."

08:39 EST Red Cat partners with Athena AI for AI, computer vision on new military dron - Red Cat Holdings announces Athena AI as a computer vision partner for the new Teal 2 military-grade drone. Australia-based Athena, an AI-enabled military decision-support company, has licensed to Red Cat its proprietary computer vision architecture, which allows high-speed tracking of objects and, at slower speeds, in-depth data exploitation. Athena's solution can identify weapons and various other objects and poses at night, as well as Identification Friend or Foe markers, such as Cyalume HALOs and IR beacons. "The Teal 2 is a mission-focused military drone, and our partnership with Athena enables us to integrate the very latest computer vision technology," said Red Cat CEO Jeff Thompson. "In military operations, every second counts, and Athena's ability to track objects at night means our drone can deliver crucial intel to warfighters and commanders, providing rapid decision-making support." By integrating Athena's technology, the Teal 2 can support Danger Close Fire Missions at night. The Forward Line of Own Troops can be detected, recognized and geolocated in comparison with the enemy, allowing for precision and safe fires on the target.

08:37 EST Intelligent Bio Solutions regains compliance with Nasdaq listing requirement - Intelligent Bio Solutions announced that on February 27, 2023, the Company received a notification from the Listing Qualifications Department of The Nasdaq Stock Market informing the Company that it has regained compliance with Nasdaq Listing Rule 5450(a)(1). As a result, the Company is now in compliance with the Minimum Bid Price Requirement for continued listing and Nasdaq considers the matter closed.

08:36 EST Allogene Therapeutics announces publication of case review in Molecular Therapy - Allogene Therapeutics announced the publication of a case review in Molecular Therapy of the single patient treated with ALLO-501A who presented with a chromosomal rearrangement. The findings from this report advance the understanding of the presence of genomic variability at the chromosomal level in mature lymphocytes expanding the knowledge in the field of gene and cell therapy. The Company's case report details a chromosome 14 inversion in a patient treated with gene edited cells. Initial caution surrounding this case led to a U.S. Food and Drug Administration clinical hold in October 2021 across the Company's AlloCAR T clinical trials. An extensive investigation concluded that the chromosomal inversion was unrelated to TALEN gene editing or Allogene's manufacturing process and had no clinical significance, resulting in a lift of the clinical hold three months later. "As the leader in the development of allogeneic CAR T cell treatments, we understand our responsibility to patients as well as the important role we play in advancing this rapidly developing field," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "As we look to deliver on the promise of allogeneic CAR T cell products, this case highlights the need to understand cell-intrinsic biology as well as the theoretical effects of genomic manipulations. Through the efficient investigation of this event, we have increased our understanding of the frequency and mechanisms of chromosomal variability in normal mature T cells without connection to genomic manipulations."

08:35 EST Sigma Additive Solutions retains advisor to explore strategic alternatives - Sigma Additive Solutions announced that it has retained Lake Street Capital Markets as its financial advisor in connection with the company's consideration of a range of strategic alternatives designed to enhance shareholder value, including a possible strategic investment, acquisition, merger, business combination, or similar transaction.

08:35 EST NuZee announces partnership to market TiMELESS sealing technology - NuZee announces a partnership agreement to market a new, patented Japanese technology, TiMELESS, in the U.S. and Mexico. TiMELESS is a new flexible film sealing technology that eliminates the need for one-way plastic degassing valves, which are very common in the coffee packing, pet food, and other various industries. TiMELESS was developed in 2018 by MIB Co., Ltd., a Tokyo-headquartered trading company specializing in the production and sale of packaging and packages, in collaboration with Nagase & Co., one of Japan's largest publicly traded companies. As part of the joint marketing agreement, NuZee will introduce TiMELESS technology and packaging using the TiMELESS technology to its customers in the U.S. and Mexico. NuZee is in discussions with some of the top coffee manufacturers in the US and Mexico to implement TiMELESS bag sealing technology which could eliminate the need for one-way degassing valves.

08:34 EST Vistagen granted patent for PH80 nasal spray from USPTO - Vistagen announced that the U.S. Patent and Trademark Office, or USPTO, has granted a U.S. patent for Vistagen's PH80 nasal spray for treatment of migraine. The newly issued patent will be in effect until at least 2040.

08:32 EST Workhorse Group announces board of directors transition - Workhorse Group (WKHS) announced that two new board nominees, Jean Botti and Brandon Torres Declet, will stand for election at the 2023 Annual Meeting of Stockholders. As part of the board's ongoing director refreshment process, Gerald Budde, Michael Clark, Harry DeMott and Benjamin Samuels do not intend to stand for re-election at the Annual Meeting. Following the Annual Meeting, Workhorse's board will comprise eight directors, seven of whom will be independent. Botti currently serves as Chief Executive Officer and Chief Technology Officer of VoltAero SA, an electric aircraft company. Torres Declet currently serves as Chief Executive Officer and Chairman of the Board of Unusual Machines and previously served in various leadership roles including as Chief Executive Officer and Director at AgEagle Aerial Systems (UAVS).

08:31 EST Ballard Power, First Mode sign order for 30 additional hydrogen fuel cells - Ballard Power Systems and First Mode announced a purchase order for Ballard to supply First Mode with 30 hydrogen fuel cell modules - totaling 3 megawatts - to power several hybrid hydrogen and battery ultra-class mining haul trucks. This is the equivalent of approximately 4,000 horsepower. The 30 Ballard hydrogen fuel cell modules will be integrated into clean energy powerplants built in Seattle, Washington and installed into ultra-class haul trucks to be operated at First Mode's Proving Grounds in Centralia, Washington. These trucks are estimated to save 2,600 tons of diesel fuel each year.

08:29 EST Mobilicom to undertake share buyback of small parcel holdings - Mobilicom announced it intends to undertake a share buyback of small parcel holdings. Following Mobilicom's listing on the Nasdaq stock exchange in the U.S. and with A$19 million cash on its balance sheet as of December 31, 2022, the Company undertook a strategic and operational review of its business operations and decided to further strengthen its efficient capital management and shareholder value through steps including this share buyback. The Sale Facility will allow those shareholders who hold less than A$500 of shares to sell their shares cost effectively without incurring brokerage or other transaction costs, while also assisting the Company to reduce the costs associated with servicing smaller shareholdings.

08:24 EST iCAD announces new real-world clinical evidence on ProFound AI - iCAD announced new real-world clinical evidence to be presented at the European Congress of Radiology, ECR, 2023 meeting confirms ProFound AI boosts radiologists' efficiency and accuracy. The Company is also showcasing its Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools in booth #AI-14 at the meeting, which is taking place in Vienna from March 1-5. "iCAD's comprehensive suite of breast AI solutions offers clinically proven benefits to clinicians and patients alike," said Stacey Stevens, President and CEO of iCAD, Inc. "A growing number of leading imaging facilities worldwide trust our technologies to detect cancer and stop it in its tracks - streamlining workflow, improving accuracy, and personalizing results like never before." In a research presentation session on Friday, March 3 from 16:00-17:30 CET, Kathy Schilling, MD, Medical Director, Christine E. Lynn Women's Health & Wellness Institute, Boca Raton Regional Hospital, USA, will present findings from a study titled "Real-world breast cancer screening performance with digital breast tomosynthesis before and after implementation of an artificial intelligence detection system."

08:22 EST Centessa appoints Patrick Yue as SVP, clinical development, innovative medicines - Centessa Pharmaceuticals announced the appointment of Patrick Yue, MD, to Centessa's management team as Senior Vice President of Clinical Development, Innovative Medicines. In this newly created role, Dr. Yue will primarily focus on select pipeline programs, including SerpinPC, MGX292 and orexin agonists. Prior to joining Centessa, Dr. Yue was Vice President of Clinical Science at Global Blood Therapeutics, where he oversaw four development programs, including voxelotor a treatment for sickle cell disease.

08:20 EST Savaria to sell Handicare to Cognia, terms not disclosed - Savaria Corporation entered into an agreement with Drive AS, a subsidiary of Cognia AS, pursuant to which Cognia would acquire all of the issued and outstanding shares of Handicare AS, subject to customary closing conditions and regulatory approvals. The Transaction is expected to close in late March or early April 2023. Based in Moss with service depots across Norway, Handicare AS focuses on commercial adaptations including emergency-use police, fire and rescue, and paramedic vehicles. They also provide local services for personal-use mobility adaptations.

08:20 EST Myriad Genetics announce support for new screening practice guidlines from NSGC - Myriad Genetics announced its support for the first evidence-based expanded carrier screening practice guidelines for reproductive risk assessment published by the National Society of Genetic Counselors, NSGC, in the Journal of Genetic Counseling. NSGC's guidelines support equitable access and care to all patients looking to start or grow their families by recommending that "ECS be made available for all individuals considering reproduction and all pregnant reproductive pairs."

08:18 EST R1 RCM releases its 2022 ESG report - R1 RCM released its 2022 Environmental, Social, and Governance, ESG, report, highlighting its commitment to purpose-driven work and to creating a positive impact for the communities it serves. "Our talented global team of more than 27,000 colleagues bring the R1 mission to life each day. There are countless examples over the last year of R1 team members delivering excellence through purpose-filled work on behalf of our customers, employees, communities and shareholders," said Lee Rivas, R1's chief executive officer. "Together, we will continue to translate our ESG vision into action as we deliver technology-driven solutions that help providers improve their financial performance and enable a positive experience for the patients they serve."

08:16 EST Infinera unveils portfolio of coherent optical subsystems - Infinera unveiled a new portfolio of coherent optical subsystems and coherent pluggable optical engines designed to help network operators cost-effectively keep up with the relentless growth in bandwidth demand while streamlining operations and reducing carbon footprint. The new solutions include a line of high-performance transmit-receive optical sub-assemblies, innovative programmable digital signal processors, and a line of high-performance, intelligent pluggable optical transceivers. Infinera's line of in-house-developed optical subsystems leverages an innovative building block approach whereby subsystems can be mixed and matched flexibly, maximizing the value of each element, providing more solution options for customers, and simplifying integration into in-house and third-party optical engines.

08:15 EST Nuwellis reports inducement grants under Nasdaq listing rule - Nuwellis announced that, effective February 23, 2023, the Company's independent directors approved equity awards under Nuwellis' 2021 Inducement Plan, as material inducements to six individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with Nuwellis, Inc., the individuals, who were not previously employees or directors of Nuwellis, received options to purchase an aggregate of 2,514 shares of the Company's common stock. The option awards have an exercise price of $8.27 per share, the closing price of Nuwellis' common stock on February 23, 2023, the date of the grants.

08:14 EST BioNTech announces establishment of interdisciplinary mRNA excellence center - BioNTech announced that the Company and the Weizmann Institute of Science signed a Memorandum of Understanding, MoU. As part of this MoU, scientists from a variety of disciplines from BioNTech and the Weizmann Institute will collaborate in basic and applied research with the aim to better understand various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The joint research will be conducted at BioNTech's newly established mRNA Excellence Center and in Weizmann Institute laboratories. The MoU supports BioNTech's long-term strategy to discover, research and develop innovative vaccines and therapies for diseases with high unmet medical need. The Company's mRNA Excellence Center will be based within the Weizmann Science Park in Ness Ziona. BioNTech expects the center to start operations by the end of 2023. "We are pleased to establish mRNA research laboratories on the campus of the Weizmann Institute of Science," said Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech. "Our initiative aims to foster collaborations with top researchers to advance multidisciplinary research and accelerate the development of innovative solutions to tackle some of the world's most pressing health challenges."

08:13 EST Infinera launches next-generation GX Series Compact Modular Platform - Infinera unveiled the evolution of its GX Series Compact Modular Platform solution with new innovations including its next-generation high-performance 1.2 Tb/s optical engine ICE7 and a revolutionary multi-haul optical line system. This latest set of enhancements highlights the power and flexibility of the GX platform, providing network operators with a seamless and future-proof end-to-end networking solution. Reducing cost per bit by as much as 30% and power per bit by as much as 60%, the GX platform and ICE7 optical engine will enable network operators to cost-effectively meet rapidly growing bandwidth demands and provide differentiating services to their customers.

08:12 EST Microchip announces PDS-204GCO PoE switch - PoE switches designed for outdoor use in smart buildings and cities enable services ranging from public Wi-Fi and video surveillance to connected streetlights that increasingly need better reliability and cybersecurity protection. Extending the industry's family of PoE switches with the high industry-standard outdoor protection for these applications, Microchip Technology announces its PDS-204GCO switch that adds increased cyber protection plus the redundancy required for high network availability in mission-critical applications with long-distance connectivity.

08:11 EST Augmedix appoints Rod O'Reilly as non-executive chairman of the board - Augmedix announced that Rod O'Reilly has been named to the Augmedix Board of Directors as non-executive chairman. Mr. O'Reilly has spent more than 25 years in executive leadership, most recently as EVP and President of Change Healthcare's Software and Analytics Division, and previously held numerous senior executive roles at McKesson Technology Solutions.

08:09 EST Quantum announces partnership with WaitTime - Quantum announced a partnership with WaitTime, an industry leader in crowd intelligence analytics, to deliver a certified solution that provides real-time crowd intelligence using video surveillance data captured and stored by Quantum's Unified Surveillance Platform, or USP. Quantum certified WaitTime AI software to run effectively on USP and offer easy deployment to organizations that want to maximize the value of their video surveillance data, like extracting crowd intelligence insights intended to deliver a better customer experience. USP can manage and run multiple physical security applications on one single unified infrastructure, including analytics applications like WaitTime.

08:08 EST Ambrx Biopharma announces ACE-Breast-02 trial meets endpoint - Ambrx Biopharma announced that it has been informed by its partner, NovoCodex Biopharmaceuticals, that an interim analysis for ACE-Breast-02, a randomized Phase 3 breast cancer clinical trial investigating Ambrx's ARX788, an anti-HER2 antibody drug conjugate, or ADC, has met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater progression free survival, or PFS, benefit compared to the active control. ACE-Breast-02 is a randomized, controlled pivotal Phase 3 clinical trial of humanized anti-HER2 monoclonal antibody-AS269 conjugate in the treatment of HER2 positive patients with locally advanced or metastatic breast cancers in China. The trial enrolled 441 HER2 positive breast cancer patients who have been previously treated with taxane and trastuzumab. Eligible subjects were randomly assigned in a 1:1 ratio to receive ARX788 or the control drugs, lapatinib combined with capecitabine. The primary endpoint was PFS based on Blinded Independent Review Committee, or BIRC, assessment. An interim analysis was conducted by an Independent Data Monitoring Committee, or IDMC, when two thirds of the PFS events occurred. After reviewing the interim results, the IDMC informed NovoCodex that the ACE-Breast-02 study met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater PFS benefit compared to the control. Based on the results from the interim analysis, NovoCodex plans to submit a communication application to seek marketing approval in China pending discussion with National Medical Products Administration, or NMPA.

08:07 EST PDS Biotechnology announces publication of PDS0301 study - PDS Biotechnology announced that clinical research conducted by the NCI, one of the Institutes of the National Institutes of Health, was published in the peer-reviewed journal, International Immunopharmacology. The clinical study assessed immune changes in relation to the dose level and dosing schedule of PDS0301, NHS-IL12, a novel investigational fusion protein consisting of a tumor-targeting antibody conjugated to Interleukin 12. The study also evaluated the correlation of several treatment-related immunological changes with clinical responses. As described in the paper, titled, "Immune correlates with response in patients with metastatic solid tumors treated with a tumor-targeting immunocytokine NHS-IL12," the researchers at the NCI evaluated a subset of 23 patients with advanced cancers who participated in a Phase 1 clinical trial of PDS0301. Patients were dosed every 2 weeks with PDS0301 at one of two levels - 12.0 mcg/kg and 16.8 mcg/kg - or every 4 weeks at 16.8 mcg/kg to identify dosing amounts and regimens of PDS0301 that correlate with higher levels of immune activation, including quantities of CD8 T cells, immune suppressive T regulatory cells, natural killer cells and natural killer T cells. The ability to limit exposure of IL-12 in the circulating blood, and to increase its presence within the tumors constitutes a significant advancement in the development of cytokine-based immunotherapy. "The research published by the NCI demonstrates the potential of PDS0301 as a tumor-targeting IL-12 and its ability to stimulate immune activation and increase the frequency of CD8 T cells and certain NK cell subsets to potentially overcome the immunosuppressive tumor microenvironment," stated Dr. Lauren Wood, Chief Medical Officer of PDS Biotech. "Importantly, this study appears to demonstrate the safety and tolerability of biologically active doses of PDS0301 and reports increases in specific immune cells that were associated with PDS0301 administration and improved clinical outcomes."

08:05 EST USPH acquires 80% of equity interests of physical therapy practice for $6.2M - U.S. Physical Therapy announced an acquisition of a physical therapy practice with one large clinic. USPH acquired 80% of the equity interests of the physical therapy practice with the practice's founder and owners retaining 20%. The purchase price for the 80% equity interest was approximately $6.2M. The business generates approximately $3.2M in annual revenue and has approximately 27,000 patient visits per year. Chris Reading, Chief Executive Officer, stated, "This young and very capable husband and wife team has built an amazingly successful single-site facility that has a very strong presence in their community. We look forward to assisting them in expanding their well-regarded services to additional locations in the surrounding areas."

08:05 EST Qurate Retail appoints Bill Wafford as CFO - Qurate Retail GroupSM, part of Qurate Retail, announced the appointment of Bill Wafford as its CFO. Wafford has more than 25 years of experience in corporate finance, management consulting and executive leadership across retail, consumer goods and digital commerce businesses. He will report to David Rawlinson II, President and CEO of Qurate Retail, James Hathaway, who had been serving as Interim CFO since August 2022, will become the CFO of QVC US. Wafford joins Qurate Retail Group from Everlane, a digitally native apparel brand, where he was the CFO. Prior to Everlane, he served as CFO for retail companies such as JCPenney, The Vitamin Shoppe and Thrasio. He also previously served as Partner in the advisory practice group at KPMG, after holding various executive finance roles with Walgreens Boots Alliance, Target and Archstone Consulting. Wafford has an MBA in Finance / Strategy from Indiana University - Kelley School of Business and a BS in Economics from University of California, Riverside. Wafford officially begins with the company on March 20. He will be based at the company's global headquarters in West Chester, Pa.

07:52 EST NanoXplore receives patent approval for SiG anode additive solution - NanoXplore received patent approval for its Silicon/Graphene battery anode material solution under the trademark SiG. These patents cover battery cell production processes and are filed in several countries, namely the United States, Germany, China, Canada, the UK and South Korea. These patents also cover a range of different chemistries and extend to all cylindrical cell form factors. GrapheneBlack acts as a coating agent around Silicon alleviating swelling and dislodgment of particles making the cell safer and more reliable. Performance Highlights: In addition, the Corporation has demonstrated strong performance of its SiG anode technology solution when incorporated, as an additive, in battery cells: Driving Range: NanoXplore's patented technology increased vehicle range by 8-10% or 40 kilometers for a typical Electric Vehicle. Charging Time: Due to SiGTM high electrical conductivity, charging speed was reduced substantially to between 10 and 13 minutes. Charging speed could go as low as 10 minutes, without compromising battery life. It can go beyond that point for applications such as for military applications, power tools or consumer electronics. Safety: SiG based cells are 10% cooler than typical potentially flammable Li-ion batteries. Hence, with the help of GrapheneBlack, they are safer due to less risk of thermal runaway and explosions.

07:50 EST Atlantica Sustainable Infrastructure sees 2023 adjusted EBITDA $790M-$850M - 2023 expected CAFD in the range of $235M to $260M.

07:47 EST Sabre says Kurt Ekert to replace Sean Menke as CEO, effective April 27 - Sabre announced that Sean Menke, currently Chair of the company's Board and its CEO, will transition to be solely Sabre's Executive Chair of the Board, effective April 27. At that time, Kurt Ekert, currently President of Sabre, will also become the company's CEO, reporting to the Board of Directors. Ekert has also been nominated as a director for election at Sabre's 2023 Annual Meeting, to be held on April 26. These moves are being made as part of the company's and the Board of Directors' ongoing succession planning. Ekert joined Sabre in January 2022 as President as part of the company's long term succession plans, as it split the role of president and CEO.

07:47 EST Zevra Therapeutics begins trading as ZVRA - Zevra Therapeutics will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open, March 1, 2023. The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwavering commitment to the rare disease community as it pursues its primary mission to deliver life-changing treatments to people with rare conditions, their families and caregivers who desperately need better options. Zevra expects several key milestones in 2023, including the planned resubmission of the New Drug Application for arimoclomol to the FDA as early as Q3 2023, an interim and final data readout for KP1077 in IH, and the potential achievement of one or more certain commercial sales milestones for our partnered asset, AZSTARYS, during FY 2023.

07:40 EST Guru Organic Energy appoints Grar as Chief Revenue Officer - GURU Organic Energy announces the appointment of Rajaa Grar as Chief Revenue Officer for the Company, effective immediately. From July 2020 until August 2022, she was Chief Marketing and Digital Officer at Nutrabolt, owner of C4 Energy, where she successfully refocused the company's marketing efforts, resulting in doubling the company's digital and total revenue over a two-year period.

07:36 EST Vivos acquires certain rights, patents from Advanced Facialdontics - Vivos Therapeutics announced it has acquired certain U.S. and international patents, product rights, and other miscellaneous intellectual property from Advanced Facialdontics, a company holding propriety technology on certain FDA 510(k) cleared dental and medical devices. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product portfolio and revenue potential. AFD's flagship product is the Preventive Oral Device, known as the POD. AFD's second FDA 510(k) cleared product is known as the Night Block. Kirk Huntsman, Vivos' Chairman and Chief Executive Officer, commented "This acquisition adds important technology and products that immediately open up new markets to us with significant revenue potential. We can now offer dentists and patients a complete line of lower cost products with higher margins alongside our existing Vivos Method treatments to meet whatever clinical needs and financial price points they may require. In this transaction, we have also acquired several U.S. and international patents, some of which were granted in just the past few months that will allow us to preserve and protect our first mover advantages in the U.S. and Canada as well as other international markets. TMD and Bruxism are very common, but often difficult to treat. We believe this highly effective technology from AFD is a real breakthrough, with significant applications across many different kinds of existing oral appliances, such as clear aligners, palatal expanders, and traditional mandibular advancement devices, as well as our own CARE devices that are part of The Vivos Method."

07:30 EST Complexity Gaming signs sponsorship agreement with H-E-B - Complexity Gaming has signed an exclusive sponsorship agreement with H-E-B, a Texas-based multi-format retailer. With a growing footprint of more than 420 stores throughout Texas and Mexico, and 117 years in business, H-E-B is committed to serving its local communities. Like Complexity, H-E-B values heart, drive, and innovation making it a perfect partnership. Complexity, in collaboration with Spark Foundry, will promote these shared values to GameSquare's content creator network, social channels, and various Twitch content streams, that have an aggregated following of more than 175 million.

07:26 EST Aldebaran Resources reports results from two holes at Altar copper-gold project - Aldebaran Resources reporst additional results from two holes at its ongoing drilling campaign at the Altar copper-gold project in San Juan Province, Argentina. Hole ALD-22-222 was drilled in an area with no previous drilling and was designed to test a favourable geophysical signature coincident with a strong, multi-element talus fines geochemical anomaly at surface. Drill hole ALD-22-222 was terminated at 1,226.00 m depth. Hole ALD-22-223 represents a 500 m step out from previously drilled hole ALD-22-221 and was designed to test a geophysical anomaly in an area of favourable geological and geochemical information gleaned from nearby shallow drilling. Hole ALD-22-223 was terminated at 1,287.50 m depth. The Company notes that its CuEq formula has changed from previous press releases and that the updated CuEq formula incorporates estimated recoveries for all reported commodities. Highlights: ALD-22-223: 1,167.50 m of 0.48% CuEq from 120 m depth; Including 418.00 m of 0.67% CuEq from 848 m depth; Hole ended in mineralization. ALD-22-222: 25.30 m of 0.40% CuEq from 196.70 m depth; 48.00 m of 0.27% CuEq from 248 m depth; 378.00 m of 0.46% CuEq from 848 m depth; Hole ended in mineralization. John Black, CEO commented: "Anytime you intersect over a kilometre of good-grade mineralization, it's exciting. In the case of hole 223, it's very encouraging as the mineralization starts near surface and is in an area with no previous drilling. This opens a very large area for potential resource expansion and demonstrates that the Altar deposit, while already very large, has the potential to become significantly larger."

07:23 EST Microbix Biosystems supporting Australian point-of-care testing program - Microbix Biosystems announces that its Quality Assessment Products, QAPs, are now supporting test accuracy within a program to provide Point-of-Care Testing for Sexually-Transmitted Infections in remote communities across Australia. An initial supply of QAPs has been delivered to the end-customer via Microbix's regional distributor, r-Biopharm Australia Pty Ltd, for support of the program. The program being supported by QAPs is directed to improving the health of Australians in more-remote areas by using PoCTs to improve access to diagnosis and treatment of STIs. Microbix is supplying its QAPs formatted onto the FLOQSwabs of its strategic partner, Copan, under the PROCEEDxFLOQ brand. The PROCEEDxFLOQ QAPs have been formatted as multiplex positives that contain whole-genome MDx targets for each of the three targeted STI pathogens and as STI-free negatives, each with sample-adequacy control. Microbix's QAPs dry FLOQSwab formulations are validated to be stable for two years at temperatures as high as 30 Celsius - a critical property for use in the targeted regions of Australia.

07:22 EST Tilray's CANACA launches collection of terpene rich products - Tilray Brands announced the launch of the latest innovations by its Canadian cannabis lifestyle brand, CANACA. Introducing Bursts and Darts, CANACA reveals its newly added 'potently Canadian' products across Canada including four milled flower-based products. Joining the CANACA family, the four new SKUs include Fruitsplosion and Parmigiano Dankiano Bursts, as well as Fruitsplosion and Magic Mochaccino Darts; produced from a hand-selected curation of terpene-rich strain combinations, these new CANACA SKUs not only feature higher potencies - they are also crafted to feature its unique taste profiles and aromas, while offering elevated consumer experiences.

07:22 EST Tetra Technologies adopts Tax Benefits Preservation Plan - TETRA Technologies announced that its Board of Directors has adopted a Tax Benefits Preservation Plan intended to preserve the availability of the Company's existing net operating loss carryforwards, or NOLs, and other tax attributes. As of December 31, 2022, the Company has U.S. federal NOLs of approximately $411M as well as other Tax Attributes that may be available to reduce the Company's future U.S. federal income tax expense and represent significant value to the Company. However, the Company's ability to use its Tax Attributes may be materially reduced or eliminated if it were to experience an "ownership change," as defined under Section 382 of the Internal Revenue Code. In general, a change of ownership would occur if stockholders that own at least 5% or more of the Company's outstanding common stock increased their cumulative ownership in the Company by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The Tax Plan reduces the likelihood that changes in the Company's investor base would limit the Company's future use of its Tax Attributes, which would significantly impair the value of such Tax Attributes. TETRA reported 2022 income before taxes of $11.9M.

07:20 EST Enbridge provided update on strategic priorities and financial outlook - Enbridge provided an update on its strategic priorities and financial outlook. Highlights include: four growing businesses with best-in-class first-choice franchises; visible C$3+ billion of annual investment in natural gas infrastructure, C$1+ billion in liquids infrastructure, and C$1+ billion in renewable power generation; New Energy Technology team advancing contracted infrastructure in Renewable Natural Gas, Carbon Capture and Sequestration and Hydrogen in the U.S. and Canada Expected average annual growth rate of 4%-6% in EBITDA and earnings per share and ~3% DCF per share over the 2022-2025 Plan period; expected average annual growth rate of ~5% post 2025 for EBITDA, DCF and EPS; Internally generated financial capacity for investment after dividends of ~C$6 billion per year on average over the Plan period, while maintaining a strong balance sheet. The company announced C$3.3B of new accretive investments including: adding C$2.4B of new gas transmission modernization and utility capital to our secured capital program which will be added to rate base and drive earnings and cash flow growth; announced the intention to undertake a binding open season for up to 95 kbpd on the Flanagan South Pipeline system which is expected to begin in March; in combination with the FSP open season, Enbridge announced plans to construct the Enbridge Houston Oil Terminal for a capital cost of $240m which is expected to have an initial capacity of 2.5 MMbbls of storage with potential to expand capacity up to 15 MMbbls; Entered into an agreement to acquire 35 Bcf of premium Gulf Coast gas storage assets for $335M, further supporting our customers and our U.S. Gulf Coast LNG export strategy; entered into an agreement to invest $80M in a leading RNG infrastructure company - Divert; Gas Distribution and Storage is moving forward with a plan to build a pipeline to supply ArcelorMittal Dofasco in Hamilton, Ontario with natural gas, supporting the largest GHG emissions reduction project in the province.

07:19 EST Paramount Gold Nevada announces term sheet financing of up to $15M - Paramount Gold Nevada announced that it has executed a non-binding term sheet with Sprott Resource and Streaming Royalty, for a Royalty Convertible Note providing for minimum proceeds of $10M and maximum proceeds of up to $15M. While substantial technical and legal due diligence has been completed by Sprott Streaming, there can be no assurance that the proposed financing will be completed. The proceeds of the financing will be used to fund the continued permitting of the proposed Grassy Mountain Gold Mine in eastern Oregon, for general corporate purposes and for the repayment of the company's outstanding convertible notes maturing in September of this year. Paramount CEO, Rachel Goldman commented, "We are delighted to welcome Sprott Streaming as an important partner in our continued efforts to advance Grassy Mountain through permitting and ultimately to a construction decision. Against the backdrop of a challenging equity market for junior resource companies, the financing contemplated by the term sheet we have executed will provide non-dilutive capital that is expected to fund the Company through to the receipt of permits at Grassy."

07:17 EST Lexasure enters business combination agreement with CEMAC - Lexasure Financial Group and Capitalworks Emerging Markets Acquisition announced a definitive business combination agreement to provide Lexasure with a path to becoming a publicly listed company through a new Cayman Islands holding company, Lexasure Financial Holdings, that will acquire both Lexasure and CEMAC. Lexasure enables local direct insurers to compete across emerging Asia through innovative product solutions designed to empower insurers, companies, and individuals to manage risk more effectively and accelerate their growth. These product solutions include Lexasure's recently launched comprehensive mobile apps, Vivacity and Flourish, which are designed to promote healthy lifestyles, improve engagement for health insurance providers, and provide farmers with insurance coverage and mobile technology in the event of the failure of crops and livestock, respectively. In its traditional lines of business, Lexasure underwrites reinsurance and insurance and serves as a broker for a diverse set of industries, working with over 60 primary insurers across 22 countries in Asia, the Middle East, and North America. Lexasure is led by a senior leadership team comprised of insurance veterans and technology leaders with over 150 years of combined industry experience. Lexasure's Chairman, Richard Goh, has over 40 years of experience in the insurance business and is the former CEO of a Labuan composite insurance group, which has operations in Indonesia, the Philippines, and Myanmar. Lexasure's founder and CEO, Ian Lim, has over 25 years of experience in the reinsurance and insurance industries, having previously served in senior leadership roles at BMS Asia and SiriusPoint. CEMAC was listed in December 2021 with $234.6 million in trust, with the goal of identifying a prospective target business with high growth and cross-border operations in middle-income emerging markets, with the ability to replicate its business model sustainably across other emerging markets. The business combination agreement has been unanimously approved by the Board of Directors of CEMAC and the Board of Directors of Lexasure and is subject to the satisfaction of certain closing conditions, including the approval of the stockholders of CEMAC. The transaction values Lexasure on a pre-money equity value of $250 million, which will be paid by Pubco to Lexasure shareholders by delivery of newly issued ordinary shares of Pubco, each valued at the price per share paid to CEMAC shareholders who elect to redeem their CEMAC shares in connection with the transaction. The shareholders of Lexasure will have the contingent right to receive up to an additional 5 million Pubco ordinary shares subject to achieving defined financial performance metrics. At the closing of the transaction, CEMAC security holders will receive equivalent securities in Pubco in exchange for their CEMAC securities, and both CEMAC and Lexasure will become wholly-owned subsidiaries of Pubco.

07:16 EST Novocure announces reimbursement of Optune with TMZ - Novocure announced the reimbursement and availability of Optune together with temozolomide, or TMZ, for the treatment of adult patients with newly diagnosed glioblastoma, or GBM, in France. The order registering Optune on the List of Reimbursable Products and Services, or LPPR, provided for in Article L165-1 of the Social Security Code was published in the Official Journal on February 28 and will become effective March 15.

07:14 EST Tyra Biosciences expands development of TYRA-300 into achondroplasia - Tyra Biosciences announced that it is expanding development of TYRA-300 into achondroplasia based on positive preclinical results demonstrated in a study performed in collaboration with the Imagine Institute in Paris, France. Achondroplasia, the most common form of dwarfism, is a skeletal dysplasia in which growth plate cartilage is affected, resulting in decreased growth of the long bones, vertebral bodies and skull base. These growth differences result in health complications such as cranial and spinal stenosis, hydrocephalus and sleep apnea. A specific mutation in FGFR3 causes over 97% of achondroplasia. TYRA-300, an investigational agent, is a once-daily oral FGFR3 selective inhibitor whose design may have a meaningful impact on achondroplasia and other skeletal dysplasias. In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length. Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024

07:12 EST Evoqua Water to acquire industrial water treatment service business from Kemco - Evoqua Water announced that it has acquired the Texas-based industrial water treatment service business of the former Bob Johnson & Associates from Kemco Systems, further strengthening Evoqua's service footprint in the Texas market. The deal includes the industrial water treatment service business accounts for the Houston and Waxahachie, Texas regions as well as its deionization, or DI, and carbon tank assets. The terms of the deal were not disclosed.

07:10 EST Novocure announces final patient enrolled in METIS study - Novocure announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields, or TTFields, therapy following stereotactic radiosurgery for treatment of patients with brain metastases resulting from non-small cell lung cancer.

07:09 EST Astec implements limited restructuring plan - Management continually reviews our organizational structure and operations to ensure they are optimized and aligned with achieving our near-term and long-term operational and profitability targets. In connection with this review, in February 2023, we implemented a limited restructuring plan to right-size and reduce the fixed cost structure of our overhead departments. We anticipate charges of $3.0 million to $4.0 million for employee termination costs, excluding equity award modifications, to be incurred primarily in the first quarter of 2023. No further actions are currently planned. However, additional actions may be taken as a result of management's ongoing business reviews.

07:08 EST Wendy's announces plan to redesign organizational structure - On February 16, the Board of Directors approved a plan to redesign the company's organizational structure to better support the execution of the company's long-term growth strategy by maximizing organizational efficiency and streamlining decision making. As a result of the redesign, the company expects to hold its general and administrative expense in 2023 and 2024 relatively flat versus 2022. The company expects to incur total costs of approximately $11M-$13M related to these savings, of which approximately 85% is expected to be cash expenditures.

07:05 EST Wendy's reports Q4 U.S. same-restaurant sales growth 5.9% - Reports Q4 International same-restaurant sales growth of 9.9%; Global 6.4%.

07:02 EST User reports indicate problems at Twitter, says Downdetector - Reference Link

07:01 EST Divert announces $1B infrastructure development agreement with Enbridge - Divert announced a $1B infrastructure development agreement with Enbridge, solidifying the company's leadership in solving the wasted food crisis and delivering on its mission to decarbonize the food value chain and combat climate change. In addition, Divert secured $80M in growth equity from Enbridge and also $20M led by current investor Ara Partners. The $1B infrastructure agreement will support the development of wasted food to renewable natural gas, or RNG, facilities across North America. This will accelerate Divert's expansion of anaerobic digestion facilities to sustainably convert wasted food into clean renewable energy, with the potential to offset up to nearly 400,000 metric tons of carbon dioxide annually. Divert plans to scale its facilities to every major geographic region in the U.S. to be within 100 miles of 80% of the U.S. population in the next eight years. New wasted food to RNG facilities will also be considered for Canada.

06:48 EST Macau reports February casino revenue up 33.1% to 10.32B patacas - Macau's gaming bureau reported February gross revenue from games of fortune in the region was up 33.1% year-over-year to 10.32B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link

06:42 EST MGM Resorts, BetMGM announce five-year contract extension with BCLC - MGM Resorts (MGM) and BetMGM, a joint venture between MGM Resorts and Entain (GMVHF), announced a five-year contract extension with the British Columbia Lottery Corporation, or BCLC, and its responsible gaming program, GameSense. The program, which BCLC first licensed to MGM Resorts in 2017, enhances MGM Resorts' and BetMGM's guest and customer service models by focusing on conversations with players about how to gamble responsibly.

06:26 EST ImmunoGen announces license agreement with Vertex Pharmaceuticals - ImmunoGen (IMGN) announced a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals (VRTX) rights to conduct research using ImmunoGen's ADC technology to discover novel targeted conditioning agents for use with gene editing. Following the research period for each target, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, and commercialize conditioning agents employing ImmunoGen's technology for that target. ImmunoGen will retain full rights to the ADC technology for all targets not covered by the Vertex license. As part of the agreement, Vertex will pay ImmunoGen an upfront payment of $15M. ImmunoGen is eligible to receive up to $337M in option exercise fees and development and commercial milestone payments per target. ImmunoGen will be eligible to receive tiered royalties as a percentage of worldwide commercial sales of novel licensed targeted conditioning agents by Vertex. Vertex is responsible for all research, development, and commercialization and related costs.

06:15 EST KBR technology selected for ammonia facility in the Middle East GCC region - KBR announced that its ammonia technology has been selected for a large-scale one million tons per annum low-carbon ammonia facility in the Middle East GCC region. Under the terms of the contract, KBR will provide the technology license, basic engineering design, proprietary equipment and catalyst for the low-carbon ammonia plant. The project reinforces the region's focus to emerge as a leader in low-carbon fuels by capitalizing on ammonia as a vector for clean hydrogen.

05:28 EST Nio says achieved record-breaking quarterly delivery on Q4 - "NIO delivered 40,052 vehicles in the fourth quarter of 2022, representing a solid growth of 60% year-over-year and achieving a record-breaking quarterly delivery. NIO capped off 2022 with 122,486 vehicle deliveries, representing a growth of 34% year-over-year. NIO has established itself as the most competitive premium brand in the smart electric vehicle market in China, ranking first in the premium battery electric vehicle market segments priced over RMB400,000 and RMB300,000 with the market share of 75.8% and 54.8% respectively in the fourth quarter of 2022, according to the retail sales data from China Automotive Technology and Research Center," said William Bin Li, founder, chairman and chief executive officer of NIO.

05:19 EST ING Groep announces EUR 50M share repurchase program - ING announced the start of a share repurchase program under which it plans to repurchase ordinary shares of ING Groep N.V., for a maximum total amount of EUR 50M. The purpose of the share repurchase program is to meet obligations under the share-based compensation plans. ING Group's CET1 ratio was 14.5% at the end of the fourth quarter of 2022, which is well above the prevailing CET1 ratio requirement of 10.58%. After fulfilling delivery obligations under the employee share-based compensation scheme, the buyback program has negligible impact on our CET1 ratio. The share repurchase will commence on March 1 and is expected to end no later than March 7.

05:16 EST Super Micro Computer enters close collaboration with Rakuten Symphony - Supermicro announced a close collaboration with Rakuten Symphony to deliver the next generation of servers and storage systems, for a wide range of workloads. As a collaborator with Rakuten Symphony, the two companies are providing blueprints to operators for cloud-based mobile services that utilize the most advanced servers and networking architecture, delivering a solution for operators worldwide. In addition, Rakuten Symphony can quickly offer Open RAN solutions with timely technical support and consultancy.

05:12 EST Spirit AeroSystems enters MRO agreement with Joramco - Spirit AeroSystems announced an agreement with Jordan Aircraft Maintenance Company, Joramco, to be a Spirit Authorized Maintenance, Repair and Overhaul, or MRO, center. Joramco, based in Amman, Jordan, is a maintenance, repair, and overhaul provider and the engineering arm of Dubai Aerospace Enterprise, or DAE. Joramco will provide a wide range of repairs and services of composite and metallic aerostructures to customers in the region. Under this agreement, Joramco will initially provide total nacelle repair services to both Airbus A320 and Boeing 737 aircraft in partnership with Spirit AeroSystems. Joramco and Spirit intend to expand the services to other platforms, including Boeing 777.

05:08 EST XPeng delivers 6,010 Smart EVs in February - XPeng announced its vehicle delivery results for February. In February, XPeng delivered 6,010 Smart EVs, representing a 15% increase over the prior month. In parallel with efforts to accelerate market share gains domestically, the company continued to extend its presence in international markets. In February, XPeng opened its second retail stores in both Denmark and the Netherlands. At the same time, the first European service center also started operation in Lorenskog, Norway. Starting from March, XPeng's City NGP advanced driver assistance function will be implemented on multiple models in a number of cities including Shenzhen and Shanghai, offering more XPeng customers smart driving experiences with elevated convenience.